Biomarker mPITX2 for prostate cancer prognostic application successfully validated First clinical laboratory in Germany to start offering mPITX2 testing service ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– new product/research/Molecular diagnostics Press release, Berlin, Germany and Seattle, WA, USA, May 29, 2009 (euro adhoc) [...]
Tag Archive > Prostate Cancer Prognosis
EANS-News: Epigenomics AG Receives Allowances for Key Patents in Europe
Patents cover biomarker mPITX2 for prostate and breast cancer indications ——————————————————————————– Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement. ——————————————————————————– new product/molecular diagnostics Berlin, Germany, and Seattle, WA, USA, May 13, 2009 (euro adhoc) – Epigenomics AG (Frankfurt Prime Standard: ECX), a molecular diagnostics company focusing [...]
